Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline. It uses technology platforms to reduce toxicity through chemical design and to accelerate in-licensed drugs to the clinic by matching patients with AP3 and artificial intelligence.